ReviewCurrent hypertension reports2015
PPARγ Regulation in Hypertension and Metabolic Syndrome.
Review in Current hypertension reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Anti-inflammatory potential of telmisartan compared to other antihypertensives: secondary outcomes from a randomized trial.Inflammopharmacology · 2025Trial
- Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.Journal of the American Heart Association · 2017Trial
- Occupational Organophosphorus Pesticide Exposure and Metabolic Syndrome: Implications of PPARγ.Toxics · 2026Article
- Progress in Synthesis and Pharmacology of Telmisartan.Chemistry & biodiversity · 2026Review
- Anti-Obesity Effects and Underlying Mechanisms of Total Polyphenols fromMolecules (Basel, Switzerland) · 2026Article
- A Rapid Genotyping Assay forCurrent developments in nutrition · 2026Article
- Integrative molecular simulations reveal NeuroAid II mechanisms in ischemic stroke through network pharmacology, molecular dynamics, and pharmacophore modeling.Scientific reports · 2026Article
- Why Are Internal Mammary (Thoracic) Arteries Less Prone to Developing Atherosclerosis Compared to Coronary Arteries? Do Gut Microbiota Play a Role? A Narrative Review.International journal of molecular sciences · 2025Review
- Plasma Fatty Acid Profiles Modulate PPARγ Expression in Adipose Tissue: A Lipidomic Insight Into Obesity-Related Metabolic Dysregulation.Endocrinology, diabetes & metabolism · 2025Article
- Effects of Cytokines (or Activating Factors) on Arterial Endothelial Cells.International journal of molecular sciences · 2025Review
- Butyrate Produced by Gut Microbiota Regulates Atherosclerosis: A Narrative Review of the Latest Findings.International journal of molecular sciences · 2025Review
- Mangiferin mitigates dexamethasone-induced insulin resistance in rats: insight into vascular dysfunction and hepatic steatosis.Frontiers in pharmacology · 2025Article
- Piperine's potential in treating polycystic ovarian syndrome explored through in-silico docking.Scientific reports · 2024Article
- USP18 Curbs the Progression of Metabolic Hypertension by Suppressing JAK/STAT Pathway.Cardiovascular toxicology · 2024Article
- Article
- Pioglitazone protects PC12 cells against oxidative stress injury: AnExperimental and therapeutic medicine · 2023Article
- Lysine 222 in PPAR γ1 functions as the key site of MuRF2-mediated ubiquitination modification.Scientific reports · 2023Article
- PPARγ (Peroxisome Proliferator-Activated Receptor γ) Deacetylation Suppresses Aging-Associated Atherosclerosis and Hypercholesterolemia.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Molecular docking analysis of PPARγ with phytochemicals from Moroccan medicinal plants.Bioinformation · 2023Article
- Recent findings on the cellular and molecular mechanisms of action of novel food-derived antihypertensive peptides.Food chemistry. Molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Dysregulation of peroxisome proliferator-activated receptor gamma (PPARγ) activity leads to significant alterations in cardiovascular and metabolic regulation. This is most keenly observed by the metabolic syndrome-like phenotypes exhibited by patients carrying mutations in PPARγ. We will summarize recent findings regarding mechanisms of PPARγ regulation in the cardiovascular and nervous systems focusing largely on PPARγ in the smooth muscle, endothelium, and brain. Canonically, PPARγ exerts its effects by regulating the expression of target genes in these cells, and we will discuss mechanisms by which PPARγ targets in the vasculature regulate cardiovascular function. We will also discuss emerging evidence that PPARγ in the brain is a mediator of appetite and obesity. Finally, we will briefly review how novel PPARγ activators control posttranslational modifications of PPARγ and their prospects to offer new therapeutic options for treatment of metabolic diseases without the adverse side effects of thiazolidinediones which strongly activate transcriptional activity of PPARγ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.